The Baker
Study
Throughout Dr. Baker’s career at the University of Minnesota, his prime dedication has been to teaching and research in the field of neurology.

INTRODUCTION

The Baker Parkinson’s disease study of 1941 demonstrated that vitamin B6 deficiency symptoms are identical to Parkinson’s disease symptoms. Today, the B6 deficiency is still a problem, but not addressed by medicine. The opposite is true; starting in 1975 carbidopa (benserazide later) which is taken by 89% of Parkinson’s disease patients, has the powerful ability to remove vitamin B6 from the system irreversibly, making vitamin B6 deficiency worse. Ignoring the drug-induced symptoms of vitamin B6 depletion may cause the patient to conclude that Parkinson’s disease symptoms are getting worse erroneously.

THE PATIENT PERSPECTIVE

Carbidopa or benserazide as found in Sinemet, Madopar, and other drugs are of no benefit in controlling Parkinson’s disease symptoms. Combining them with L-dopa with carbidopa or benserazide in one pill is where the problem starts. Managing this cause of vitamin B6 deficiency whose symptoms are identical to Parkinson’s disease symptoms requires a properly trained licensed caregiver to stop the carbidopa or benserazide while administering adequate amounts of vitamin B6. It is not a self-treatment event.

THE SCIENTIFIC PERSPECTIVE

TA.B. Bakerhe Baker Study

The following is a classic study by AB Baker, MD neurologist from the University of Minnesota Medical School. It posted in the Journal of the American Medical Association May 1941. Dr. Baker studied a group of fifteen Parkinson’s disease patients. The patients were taking no drugs. Dr. Baker administered vitamin B6. Six of the fifteen (40%) patients achieved significant (not complete) improvement of Parkinson’s disease symptoms while taking only vitamin B6. So what happened in this study? Parkinson’s disease symptoms decrease as dopamine levels increase. The enzyme which metabolizes L-dopa to dopamine is a vitamin B6 enzyme. The 40% of patients that achieved improvement had a vitamin B6 nutritional deficiency that prevented them from metabolizing all of the available L-dopa in their system to dopamine. The symptoms of this vitamin B6 nutritional deficiency was identical to Parkinson’s disease symptoms. With the administration of adequate vitamin B6, the symptoms caused by vitamin B6 deficiency improved leaving baseline Parkinson’s disease symptoms. 

AB Baker, MD Vitamin B6 Study


The Facts:

89% of Parkinson’s disease patients take a combination pill containing carbidopa. We do not use carbidopa.

Carbidopa binds irreversibly binds to and permanently deactivates vitamin B6 and vitamin B6 dependent enzymes.

Carbidopa Paper #1  Carbidopa Paper #2

Carbidopa can deplete vitamin B6.

Depletion Paper #1  Depletion Paper #2  Depletion Paper #3

For more information on our approach to Parkinson’s disease send an email to info@parkinsonsclinics.com or call 218-626-2220. After you send your email, we may ask for more information. All communications will be kept confidential. If you have any questions, please call us free of charge.

Would you like more information on our unique approach to Parkinson's disease care?